Cell News and Research

RSS

Breakthrough research identifies fibrin as key factor in preterm brain bleeds

Mark Petersen, MD, has seen firsthand the devastating effects of brain bleeds in premature babies. It's an exceedingly common condition that affects up to 20 percent of infants born before 28 weeks of gestation, bringing an increased risk for developmental delays and autism.

24 Jul 2024

AI model enhances DCIS diagnosis using tissue image analysis

Ductal carcinoma in situ (DCIS) is a type of preinvasive tumor that sometimes progresses to a highly deadly form of breast cancer. It accounts for about 25 percent of all breast cancer diagnoses.

24 Jul 2024

Kaempferol's promise in fighting triple-negative breast cancer

Review highlights kaempferol's potential in treating triple-negative breast cancer through various anticancer mechanisms and improving chemotherapeutic efficacy.

24 Jul 2024

Proteomic signatures enhance risk prediction for both common and rare diseases

Researchers have developed sparse prediction models combining plasma proteins and clinical data to predict the 10-year risk of 218 diseases. The study, involving over 41,000 participants, highlights the enhanced predictive power of proteomic signatures.

24 Jul 2024

WVU researchers explore immune cell interactions in multiple sclerosis

A West Virginia University immunologist is exploring how the interaction between two types of immune cells within the central nervous system covering causes multiple sclerosis to develop.

24 Jul 2024

Challenging antibiotic resistance with dual-action macrolones

A new antibiotic that works by disrupting two different cellular targets would make it 100 million times more difficult for bacteria to evolve resistance, according to new research from the University of Illinois Chicago.

24 Jul 2024

Broken String Biosciences appoints Steve Becker as Chief Commercial Officer

Broken String Biosciences (“Broken String”), a genomics company driving development of the next generation of more precise, safe, and effective cell and gene therapies, today announced it has appointed Steve Becker as Chief Commercial Officer.

24 Jul 2024

Multiplexed STED nanoscopy technique reduces photobleaching and phototoxicity in live-cell imaging

A new publication from Opto-Electronic Advances; DOI 10.29026/oea.2024.240035 discusses multiplexed stimulated emission depletion nanoscopy for multi-color live-cell long-term imaging.

23 Jul 2024

Ohio State leads multi-million dollar research on long COVID solutions

A 2022 study suggesting that blocking a single molecule could protect against severe illness in COVID-19 has led to a $15 million federal grant supporting a comprehensive effort to learn more – with finding a solution to long COVID at the center of the new research.

23 Jul 2024

Reliability of HIV viral load tests for CAB-LA PrEP questioned in new study

A single laboratory-based HIV viral load test used by U.S. clinicians who provide people with long-acting, injectable cabotegravir (CAB-LA) HIV pre-exposure prophylaxis (PrEP) did not reliably detect HIV in a multi-country study.

23 Jul 2024

GeneMAP: A new tTool for mapping metabolic gene functions

There's a glaring gap in our knowledge of cell metabolism: in many cases, we still don't know exactly how nutrients are transported into the cell.

23 Jul 2024

More types of lung cells can be infected by SARS-CoV-2 than previously thought, scientists report

Scientists at Sanford Burnham Prebys, University of California San Diego and their international collaborators have reported that more types of lung cells can be infected by SARS-CoV-2 than previously thought, including those without known viral receptors.

23 Jul 2024

Abacavir linked to increased cardiovascular risk in HIV patients, study finds

CJ Fichtenbaum et al. Abacavir is associated with elevated risk for cardiovascular events in the REPRIEVE trial. International AIDS Conference. Friday, July 26, 2024

23 Jul 2024

Long-acting injectable CAB-LA safe for HIV PrEP during pregnancy, study finds

Long-acting injectable cabotegravir (CAB-LA) was safe and well tolerated as HIV pre-exposure prophylaxis (PrEP) before and during pregnancy in the follow-up phase of a global study among cisgender women.

23 Jul 2024